Key result
CYP2C19 genotype status was not associated with transcranial Doppler pulsatility index changes in acute ischemic stroke patients on clopidogrel treatment, whereas hematocrit was identified as the major determinant factor.
Why the study?
It was hypothesized that CYP2C19 polymorphisms in clopidogrel-treated patients influence cerebral vessel viscosity, which relates to transcranial Doppler pulsatility index.
Does CYP2C19 genotype status influence Transcranial Doppler pulsatility index changes in acute ischemic stroke patients on clopidogrel treatment?
Observational (n=84)
Single-blind
No
Does CYP2C19 genotype status influence Transcranial Doppler pulsatility index changes in acute ischemic stroke patients on clopidogrel treatment?
CYP2C19 genotype status does not appear to influence cerebral vessel pulsatility index changes in ischemic stroke patients on clopidogrel, whereas hematocrit is a major determinant of these changes.
Answers are grounded in this paper and cite their sources.
CYP2C19 genotype should not guide pulsatility index monitoring on clopidogrel; leaves open hematocrit's role and need for prospective validation.
Background: We hypothesized that cytochrome P450 2C19 (CYP2C19) polymorphisms in clopidogrel-treated patients would influence cerebral vessel viscosity, which was related to transcranial Doppler (TCD) pulsatility index (PI).Hence, we explored the relationship between the CYP2C19 genotype status and the TCD PI changes in acute ischemic stroke patients on clopidogrel treatment using serial TCD examinations.Methods: Patients (aged ≥40 years) who developed ischemic stroke within 7 days of onset of symptom from June 2018 to May 2019 were recruited for this study.Patients with high-risk cardiac sources of emboli, or stroke of other determined etiology as a stroke subtype, were excluded from the study.TCD was performed 5 (±2) days and followed up 180 (±30) days after onset of stroke.Results: Eighty-four patients were enrolled for this study.Patients were categorized into decreased and increased PI groups.Good genotype for clopidogrel metabolism was found in 38% of the decreased-PI patients and 25% of the increased-PI patients (p=0.252).CYP2C19 genotype status was not associated with PI changes in both groups.Hematocrit (Hct) was significantly related to PI changes.Conclusion: CYP2C19 genotype status was not related to TCD PI changes in acute ischemic stroke patients on clopidogrel treatment.Hct was the major determinant factor of PI.The negative association of Hct with cerebral blood flow velocity and its positive association with blood viscosity are plausible explanations for this phenomenon.
No takes yet. Share an insight, caveat, or question.
Oh et al. (2020) conducted an observational in Acute ischemic stroke (n=84). CYP2C19 genotype status (good metabolizer) vs. CYP2C19 genotype status (poor metabolizer) was evaluated on Transcranial Doppler pulsatility index (PI) changes (p=0.252). CYP2C19 genotype status was not associated with transcranial Doppler pulsatility index changes in acute ischemic stroke patients on clopidogrel treatment, whereas hematocrit was identified as the major determinant factor.
Synapse has enriched 10 related papers. Consider them for comparative context: